Clinical Trials on Difficult Intravenous Access in Japan
Total 13 results
-
PfizerCompletedClostridium Difficile Associated DiseaseJapan
-
Children's Hospital of PhiladelphiaAgency for Healthcare Research and Quality (AHRQ)RecruitingIntubation Complication | Intubation; Difficult | Failed or Difficult Intubation, SequelaUnited States, Canada, Japan, Italy, New Zealand, Singapore, Australia, Austria, Germany, India, United Kingdom
-
Sanofi Pasteur, a Sanofi CompanyCompletedClostridium Difficile InfectionJapan
-
Otsuka Pharmaceutical Co., Ltd.CompletedClostridium Difficile InfectionJapan
-
Kenichiro YamagataCompletedAtrial Fibrillation | Peripheral Vascular Disease | Vascular Access ComplicationsCzechia, Japan
-
Mitsubishi Tanabe Pharma CorporationCompletedKawasaki Disease Refractory to Initial Therapy With Intravenous ImmunoglobulinJapan
-
Astellas Pharma IncCompleted
-
BayerCompletedLiver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.Carcinoma | Liver Neoplasms | Adenoma | Liver AbscessUnited States, Japan, Singapore, Taiwan, Italy
-
Novartis PharmaceuticalsUniversity of PennsylvaniaRecruitingLong Term Safety of Patients Receiving CAR-T in an Eligible Clinical Trial or Managed Access ProgramUnited States, Japan, Australia, Germany, Spain, Belgium, Taiwan, Italy, Canada, Israel, Singapore, United Kingdom, Denmark, Finland, Norway, Austria, Netherlands, France
-
Onconova Therapeutics, Inc.TerminatedMyelodysplastic Syndrome | MDS | Refractory Anemia With Excess Blasts | RAEBUnited States, Spain, Canada, France, Australia, Switzerland, Israel, Japan, Belgium, India, Ireland, United Kingdom, Croatia, Czechia, Poland, Estonia, Germany, Italy, Austria, Hungary, Russian Federation, Sweden
-
PfizerCompletedClostridium Difficile InfectionUnited States, Spain, Belgium, Taiwan, Japan, Portugal, Colombia, Korea, Republic of, Poland, Australia, Germany, Canada, Argentina, Bulgaria, Chile, Czechia, Finland, France, Hungary, Peru, Slovakia, Sweden, United Kingdom
-
Sanofi Pasteur, a Sanofi CompanyTerminatedClostridium Difficile InfectionSweden, United States, Mexico, Philippines, Singapore, Germany, France, Canada, Australia, Peru, Colombia, Brazil, Costa Rica, Denmark, Dominican Republic, Finland, Guatemala, Japan, Korea, Republic of, Panama, Poland, Puerto Rico, ... and more
-
SymBio PharmaceuticalsCompletedAssess the Efficacy and Safety of SyB L-0501 in Combination With Rituximab in Patients With Recurrent or Relapsed DLBCLJapan